Firebrick Pharma (ASX: FRE) has been granted a patent covering the unique formulation of Nasodine Nasal Spray in South Africa.
The patent is titled: “Improved Virucidal Formulations” and expires in June 2041. It t has also been filed in the US, Europe and a number of other key markets.
The other Nasodine patent families are ‘method-of-use’ patents covering the intranasal use of povidone-iodine (PVP-I) for the common cold and pandemic viral diseases. The current patent covers the pharmaceutical composition of Nasodine, regardless of specific intended use.
The basis for the invention claimed in the patent is that the proprietary Nasodine formulation displays enhanced virucidal activity compared with PVP-I solutions alone. According to the patent, the Nasodine formulation “showed a markedly increased virucidal activity compared to other PVP-I formulations (concentrations between around 0.5% and 1.0%), at clinically- relevant exposure times of two and five minutes.”
The patent also discloses that the Nasodine formulation had enhanced antiviral activity against SARS-CoV-2 (COVID-19 virus), when compared with aqueous PVP-I solution.
A range of formulations is covered in the accepted patent claims, notably including PVP-I concentrations between 0.10% and 1.25%.
